TP53 and neoplasm: Combined treatment with mTOR and HSP90 inhibitors in vitro led to a decrease in LD50 in human and murine MPNST cell lines compared to a human fibroblast cell line (IMR90), and in vivo, to an increase in survival in tumor-bearing Nf1/p53 mutant mice [48].